A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. - Wikidata - wikimedia - TriplyDB

A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer.

A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer.

http://www.wikidata.org/entity/Q36226627

about

New Strategies for the Treatment of Solid Tumors with CAR-T Cells B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look Tumor infiltrating lymphocytes in ovarian cancer Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges Biopolymer implants enhance the efficacy of adoptive T-cell therapy.Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells.Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity Past, present and future targets for immunotherapy in ovarian cancer Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.Immunotherapy for ovarian cancer.Immunotherapeutic approaches to ovarian cancer treatment.Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells Directing cell therapy to anatomic target sites in vivo with magnetic resonance targeting Chimeric antigen receptor T cells targeting HERV-K inhibit breast cancer and its metastasis through downregulation of Ras Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells Opportunities in immunotherapy of ovarian cancer.Trial Watch: Adoptive cell transfer for anticancer immunotherapy.Immunotherapeutic strategies to target prognostic and predictive markers of cancer.Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine Chimeric antigen receptor T cells: a novel therapy for solid tumors.Adoptive immunotherapy for cancer.Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer.CAR T-cell immunotherapy: The path from the by-road to the freeway?The basics of CAR T design and challenges in immunotherapy of solid tumors - Ovarian cancer as a model.New Approaches for Immune Directed Treatment for Ovarian Cancer.Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers.Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.Advances in adult acute lymphoblastic leukemia therapy.The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells.Impact of T cell selection methods in the success of clinical adoptive immunotherapy.CAR-T cell therapy in ovarian cancer: from the bench to the bedside.Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer.Safety strategies of genetically engineered T cells in cancer immunotherapy.New Approaches in CAR-T Cell Immunotherapy for Breast Cancer.CAR-T Cells: A Systematic Review and Mixed Methods Analysis of the Clinical Trial Landscape.Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.CAR-T cells: the long and winding road to solid tumors.

P2860

Q26748500-CC7A0E92-ECB4-4A15-BC78-FB7F5F0F9670 Q26824446-53EE3F8B-5C18-473F-AFFF-B8F89866BD07 Q27021878-CBEE900E-A4B9-4704-AA46-7DC5B71CB5E8 Q27025300-BDC3782A-6E41-4D49-98C6-89102A6ABCD5 Q30614247-20E3E76B-B1C2-48D0-975B-FD94EE65AA08 Q33357295-B9E15F37-1108-4DE8-A7E4-958970B5182B Q33795137-5BCE359C-7352-4722-91E2-C540A438104E Q34748489-6CCD1BF5-FF79-44E7-AAEA-02937975C298 Q34765959-FCC1C016-686A-4F08-B996-2C002264F758 Q35034010-08321FA5-5CC3-4CD9-A904-EDFF93587545 Q35071430-1695A123-9B2F-4E00-80B1-DDCB6FCC29EB Q35164189-CBC20ADB-6878-4BD9-9562-8CE0E6A24289 Q35213535-E2B01B10-2770-4C6E-9577-033A9BD23DF8 Q35661999-F8E38949-61EB-4EF2-8A86-960808B965D0 Q36055739-E91B7FA3-CF99-42F8-8D35-2F10B8A81263 Q36110284-B2A840B4-1872-4F20-AED3-7FB5FDF813BD Q36414279-514881C1-54BF-4DB9-9617-DA59C9DE853D Q36470354-1BEE2719-9E95-4F2C-AC6B-5CF5573E48CF Q36855245-C9625A9D-7341-4F1E-8A02-610FBB459817 Q36887833-7B08A4BA-CDA5-4E4A-9E04-EAD830C55F6F Q37126006-836660C3-D37B-4E73-90D3-9927764AC641 Q37224420-4B024C49-127A-40A0-8D76-C7A916BD642C Q37728639-AE395750-08F5-486B-9741-41B91F3919F1 Q38170496-77E49E05-D758-4963-848B-8A94CB9A9597 Q38205273-D7DB9AA0-E212-4ED2-8D7D-820D8900E5DE Q38632105-236EEC4F-F4C9-4FDF-9AB7-2EEE26DE4F99 Q38748836-453AECB8-18F7-4077-B604-CB0E3ECBC77A Q38760516-7E4551FD-B145-4104-A6BB-8323112A81F3 Q38861769-EAEB6775-04AC-4C38-9811-5F9511CB3E0B Q39059681-CF1F91C7-F6FA-4181-B406-E4772B1F005A Q39459190-E0C97CED-C4E3-42F2-820A-1958F1AB5755 Q40095245-C9796C12-B0D1-449E-B8E4-D72989D53E5B Q42265908-4A3B2902-6DF0-4AB4-86D1-9B8B635B0A66 Q42362802-77800470-147E-4882-A5F0-AA700673CE78 Q47134535-464B5B6F-A44B-488D-8027-C9429460E8F5 Q47667620-84FE0121-0BCA-4E46-B70B-A3E85D39BE8D Q47761448-3D9477B0-0304-403B-92C2-A2CE4A22FEED Q49722635-5AD937B0-7C2B-4C5C-BF10-6772C0F10117 Q49843670-E7134E7E-4F2A-4EA6-A0D0-17C86A6EB623 Q49959264-AA752935-C698-474E-92D2-9A27FE9B9EAA

P2860

A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer.

http://www.wikidata.org/entity/Q36226627

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

A phase I clinical trial of ad ...... for recurrent ovarian cancer.

@ast

A phase I clinical trial of ad ...... for recurrent ovarian cancer.

@en

type

label

A phase I clinical trial of ad ...... for recurrent ovarian cancer.

@ast

A phase I clinical trial of ad ...... for recurrent ovarian cancer.

@en

prefLabel

A phase I clinical trial of ad ...... for recurrent ovarian cancer.

@ast

A phase I clinical trial of ad ...... for recurrent ovarian cancer.

@en

P1433

Q36226627-B8794EDB-7FE2-4957-BE37-FA2D0B43326A

P1476

Q36226627-B9AA3C8F-8400-4CAB-8E26-D5017CA105DF

P2093

Q36226627-0FAB8C75-2DDE-40E0-8F34-7BFCB3B094B1

Q36226627-FC65394D-7BAB-4273-AE84-40361BF5A152

P2860

Q36226627-02982175-A66E-4654-9D7C-9DBCC8802DAC

Q36226627-0935351A-9159-41E2-B098-F35E9489CC91

Q36226627-15CCC81E-5AC9-4155-A234-36454DC96129

Q36226627-1B6F3243-CDBC-4094-A1F8-DF2905BCA825

Q36226627-1FD1A08E-653B-47D5-B827-0F6F1B4EBFEA

Q36226627-1FD7ADE5-37A8-456A-8DEB-99DF3E16AF06

Q36226627-296F9FB4-041D-486D-91E3-6D07DC1B3D5B

Q36226627-2E4EC676-2FBB-4471-A7FA-1EA84C3348DC

Q36226627-3643FD37-FCF3-4D1D-BD5B-858798C72C6B

Q36226627-3B922B52-D139-4D8C-9B9F-DEFC3B1A6D41

P2888

Q36226627-7C55E514-3FE4-4263-A0F4-BB5440B2FD7B

P304

Q36226627-7DEA4339-596D-42C4-A0A3-17982FFFFE92

P31

Q36226627-B2F261EF-32BD-4D24-8DCD-E361751CBB17

P356

Q36226627-42F1B6F0-C0DD-4065-89B4-46598F07291F

P478

Q36226627-069F3597-81BF-441A-8B26-5EAC47AC601C

P50

Q36226627-FFFD8869-8B14-4C26-89B6-D708BED4C198

P577

Q36226627-9190575C-DBEB-4F8E-B9FD-782F23C67D01

P5875

Q36226627-F2D76012-7B92-45C4-872C-2AA73063BC22

P6179

Q36226627-3ACEA1B7-D088-4222-9D2C-1002AEED9B3A

P698

Q36226627-2DC05C32-3E68-4642-A642-06B3BBE981F4

P921

Q36226627-16D45E17-E334-4075-AB57-02CA7187EF77

Q36226627-8D4AE8A7-E90B-4833-AE56-C3D9D4450E42

P932

Q36226627-EDED620B-05B5-4909-AD2A-49F4DCC1F0B7

P356

1479-5876-10-157

P1433

Journal of Translational Medicine

P1476

A phase I clinical trial of ad ...... s for recurrent ovarian cancer

@en

P2093

Daniel J Powell

http://www.w3.org/2001/XMLSchema#string

Lana E Kandalaft

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Adoptive T cell therapy for cancer in the clinic

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Cancer immunotherapy comes of age

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

P2888

1479-5876-10-157

P304

157

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1479-5876-10-157

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230618156

http://www.w3.org/2001/XMLSchema#string

P6179

1031115702

http://www.w3.org/2001/XMLSchema#string

P698

22863016

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

3439340

http://www.w3.org/2001/XMLSchema#string